IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
Provided By GlobeNewswire
Last update: Dec 10, 2024
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA.
Read more at globenewswire.com0.2715
-0.01 (-5.07%)
Find more stocks in the Stock Screener
INAB Latest News and Analysis
9 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Which stocks have an unusual volume on Thursday?
10 days ago - ChartmillUnusual volume stocks in Wednesday's sessionDiscover the stocks with unexpected trading volume in today's session on the US markets.
11 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
11 days ago - ChartmillThese stocks are making the most noise in today's session.These stocks are making the most noise in today's session. Stay tuned for the latest updates!
11 days ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
11 days ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
